Login
E-mail
Password
Mostra password
Ricorda
Password dimenticata?
Iscriviti gratuitamente
Registrazione
Registrazione
Parametri
Parametri
Quotazioni dinamiche 
OFFON

MIRUM PHARMACEUTICALS, INC.

(MIRM)
RiassuntoQuotazioniGraficiNotizieRatingAgendaSocietąFinanzaConsensusRevisioniDerivati 
RiassuntoTutte le notizieRaccomandazione analistiAltre lingueComunicati stampaPubblicazioni ufficialiNotizie del settore
Notizie in altre lingue su MIRUM PHARMACEUTICALS, INC.
29/09MIRUM PHARMACEUTICALS: U.S. FDA Approves LIVMARLI (maralixibat) as the First and Only App..
29/09MIRUM PHARMACEUTICALS, INC.: Entry into a Material Definitive Agreement, Other Events, Fi..
29/09MIRUM PHARMACEUTICALS: Gets FDA's OK for Livmarli Oral Solution to Treat Chronic Itch in ..
29/09MIRUM PHARMACEUTICALS: oral drug becomes first U.S. approved Alagille syndrome therapy
29/09MIRUM PHARMACEUTICALS: FDA approves Mirum Pharma's drug for itching associated with rare ..
29/09MIRUM PHARMACEUTICALS: U.S. FDA Approves LIVMARLI (maralixibat) as the First and Only App..
29/09Mirum Pharmaceuticals, Inc Receives U.S. Food and Drug Administration Approval LIVMARLI..
29/09MIRUM PHARMACEUTICALS: Halted on Pending News; Shares Up 3% in Recent Trading
29/09MIRUM PHARMA: FDA OKs Livmarli to Treat Cholestatic Pruritus in Certain Patients
21/09MIRUM PHARMACEUTICALS: Partners With Takeda Over Developing, Commercializing Liver Diseas..
21/09Mirum Inks Japan License for Maralixibat With Takeda
13/09MIRUM PHARMACEUTICALS: Seeks Marketing Approval for Liver Disease Drug Candidate in Europ..
13/09MIRUM PHARMACEUTICALS: Submits European Marketing Authorization Application for Maralixib..
13/09Mirum Pharmaceuticals Submits European Marketing Authorization Application for Maralixi..
13/09Mirum Pharmaceuticals Submits European Marketing Authorization Application for Liver Di..
10/09MIRUM PHARMACEUTICALS: Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/09MIRUM PHARMACEUTICALS: to Participate in September Investor Conferences
20/08MIRUM PHARMACEUTICALS: Appoints Biotechnology Executive William C. Fairey to its Board of..
20/08MIRUM PHARMACEUTICALS, INC.: Change in Directors or Principal Officers, Other Events, Fin..
19/08MIRUM PHARMACEUTICALS: Appoints Biotechnology Executive William C. Fairey to its Board of..
19/08Mirum Pharmaceuticals, Inc. Announces Board Changes
11/08MIRUM PHARMACEUTICALS: Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/08MIRUM PHARMACEUTICALS: Management's Discussion and Analysis of Financial Condition and Re..
05/08MIRUM PHARMACEUTICALS, INC.: Results of Operations and Financial Condition, Financial Sta..
05/08Mirum Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June ..
05/08MIRUM PHARMACEUTICALS: Reports Second Quarter 2021 Financial Results and Provides Busines..
29/07MIRUM PHARMACEUTICALS: to Report Second Quarter 2021 Financial Results and Host Conferenc..
27/07SECTOR UPDATE: Health Care Stocks Mixed Premarket Tuesday
27/07MIRUM PHARMACEUTICALS: to Grant GC Pharma Sole Rights to Commercialize Liver Disease Drug..
27/07MIRUM PHARMACEUTICALS: and GC Pharma Enter into Exclusive Licensing Agreement to Develop ..
13/07MIRUM PHARMACEUTICALS: Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
24/06MIRUM PHARMACEUTICALS: to Present at Piper Sandler's Virtual EASL Takeaway Day
23/06MIRUM PHARMACEUTICALS: Presents Analyses From Its Rare Liver Disease Programs at the EASL..
16/06MIRUM PHARMACEUTICALS: to Showcase Analyses From Its Rare Liver Disease Programs at The I..
10/06MIRUM PHARMACEUTICALS: Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/06MIRUM PHARMACEUTICALS: Appoints Veteran Biotechnology Executive Carol L. Brosgart, M.D. t..
09/06MIRUM PHARMACEUTICALS, INC.: Change in Directors or Principal Officers, Submission of Mat..
07/06MIRUM PHARMACEUTICALS: Appoints Veteran Biotechnology Executive Carol L. Brosgart, M.D. t..
07/06Mirum Pharmaceuticals, Inc. Appoints Carol L. Brosgart, M.D. to Board of Directors
03/06MIRUM PHARMACEUTICALS: Showcases Maralixibat Transplant-Free Survival Data for Progressiv..
03/06Mirum Pharmaceuticals Showcases Maralixibat Transplant-Free Survival Data for Progressi..
26/05MIRUM PHARMACEUTICALS: to Present Maralixibat Data and Host Symposium at the 6th World Co..
11/05MIRUM PHARMACEUTICALS: Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/05MIRUM PHARMACEUTICALS: Management's Discussion and Analysis of Financial Condition and Re..
06/05MIRUM PHARMACEUTICALS: Reports First Quarter 2021 Financial Results and Provides Business..
06/05MIRUM PHARMACEUTICALS, INC.: Results of Operations and Financial Condition, Financial Sta..
06/05Mirum Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Fir..
29/04Mirum Pharmaceuticals and CANbridge Pharmaceuticals Enter into Exclusive Licensing Agre..
26/04MIRUM PHARMACEUTICALS: Receives US Patent and Trademark Notice of Allowance for Maralixib..
26/04MIRUM PHARMACEUTICALS: Receives Notice of Allowance for Methods of Use Patent for Maralix..
13/04MIRUM PHARMACEUTICALS: et Vivet Therapeutics concluent un accord mondial exclusif d'optio..
13/04MIRUM PHARMACEUTICALS: und Vivet Therapeutics gehen exklusiven weltweiten Options- und Li..
13/04MIRUM PHARMACEUTICALS: and Vivet Therapeutics Enter into Exclusive Worldwide Option and L..
13/04MIRUM PHARMACEUTICALS: And vivet therapeutics enter into exclusive worldwide option and l..
13/04MIRUM PHARMACEUTICALS: Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
12/04MIRUM PHARMACEUTICALS: Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/04MIRUM PHARMACEUTICALS: Secures Exclusive Option to Commercialize Two Therapy Programs Tar..
12/04MIRUM PHARMACEUTICALS: and Vivet Therapeutics Enter into Exclusive Worldwide Option and L..
12/04Mirum Pharmaceuticals and Vivet Therapeutics Enter into Exclusive Worldwide Option and ..
29/03MIRUM PHARMACEUTICALS, INC.: Other Events (form 8-K)
29/03MIRUM PHARMACEUTICALS: FDA Accepts Mirum's Maralixibat Application For Patients With Alag..
29/03MIRUM PHARMACEUTICALS: Announces FDA Acceptance of New Drug Application and Priority Revi..
29/03Mirum Pharmaceuticals Announces FDA Acceptance of New Drug Application and Priority Rev..
14/03Certain Common Stock of Mirum Pharmaceuticals, Inc. are subject to a Lock-Up Agreement ..
14/03Certain Options of Mirum Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Endin..
11/03MIRUM PHARMACEUTICALS: Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/03MIRUM PHARMACEUTICALS: Management's Discussion and Analysis of Financial Condition and Re..
09/03MIRUM PHARMACEUTICALS, INC.: Results of Operations and Financial Condition, Financial Sta..
09/03MIRUM PHARMACEUTICALS: Reports Fourth Quarter and Year-End 2020 Results and Provides Busi..
09/03Mirum Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Fou..
22/02MIRUM PHARMACEUTICALS: to Present at Upcoming Investor Conferences
10/02MIRUM PHARMACEUTICALS: Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/02MIRUM PHARMACEUTICALS: Completes Submission of FDA Application for Maralixibat for Treatm..
01/02MIRUM PHARMACEUTICALS: Announces Completion of Rolling NDA Submission for Maralixibat in ..
01/02Mirum Pharmaceuticals Announces Completion of Rolling NDA Submission for Maralixibat in..
1  2  3Pross.
Prossimo evento su MIRUM PHARMACEUTICALS, INC.